Clinical Scorecard: Incidence of Septic Shock in the ImmunoSep Clinical Trial
At a Glance
Category
Detail
Condition
Sepsis with macrophage activation–like syndrome or sepsis-induced immunoparalysis
Key Mechanisms
Biomarker-guided immunotherapy targeting macrophage activation with anakinra and immunoparalysis with recombinant human interferon-γ
Target Population
Patients with sepsis stratified by biological endotypes
Care Setting
Intensive Care Unit (ICU) and hospital settings managing sepsis
Key Highlights
ImmunoSep trial showed improved organ dysfunction by day 9 with biomarker-guided immunotherapy versus placebo.
New-onset septic shock occurred more frequently in immunotherapy groups (22.1%) compared to placebo (11.7%), with a crude odds ratio of 2.1 (95% CI, 1.1–4.1).
Safety findings are exploratory and statistically fragile due to small event numbers; causality with treatment remains uncertain.
Guideline-Based Recommendations
Diagnosis
Use biomarker stratification to identify sepsis endotypes: macrophage activation–like syndrome and sepsis-induced immunoparalysis.
Management
Consider precision immunotherapy with anakinra for macrophage activation–like syndrome and interferon-γ for immunoparalysis to improve organ dysfunction.
Monitor for new episodes of septic shock during and after immunotherapy treatment.
Monitoring & Follow-up
Closely observe for secondary septic shock events as clinically meaningful deterioration requiring additional organ support.
Assess temporal relationship between immunotherapy administration and onset of septic shock.
Risks
Be aware of a potential increased risk (~10% absolute difference) of new-onset septic shock with immunotherapy, though causality is not established.
Interpret safety signals cautiously due to small sample sizes and statistical fragility.
Patient & Prescribing Data
Patients enrolled in the ImmunoSep trial with sepsis stratified by endotype
Immunotherapy improved organ dysfunction but did not significantly reduce 28-day mortality; increased incidence of secondary septic shock events observed but adjudicated as unrelated or probably unrelated to study drugs.
Clinical Best Practices
Employ biomarker-guided approaches to tailor immunotherapy in sepsis.
Interpret safety data from immunotherapy trials with caution, considering underlying disease trajectory.
Incorporate secondary septic shock events into risk–benefit assessments for immunotherapy in sepsis.
Require further stratified analyses and temporal data to clarify safety signals.
